BRCA1 and prostate cancer: In addition, the insurance coverage was approved for the oral administration of talazoparib in patients with breast cancer who had BRCA1/2 mutations with PVs detected via BRACanalysis and those with prostate cancer who had BRCA1/2 mutations with PVs detected using FoundationOne CDx.